Drug WSD0628 plus radiation for recurrent brain tumor
Part of Cancer clinical trials.
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your tumor type is one of these: glioblastoma (IDH-wildtype) or grade 3/4 IDH-mutant astrocytoma
- Your cancer has come back after you already had radiation and chemotherapy
- You can return to the study site for follow-up and agree to provide tumor tissue samples if your doctors can collect them
- Your overall health scores and blood tests are in acceptable ranges (including enough blood counts and good kidney/liver function)
- You can protect your eyes from light during treatment and for 2 weeks after the last WSD0628 dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests a new approach that combines a drug (SONALA-001 or 5-ALA) with focused ultrasound to treat glioblastoma that has come back or is growing despite standard treatments. The drug makes tumor cells sensitive to sound waves, and the ultrasound waves are directed at the tumor using MRI guidance. This may help damage cancer cells while sparing healthy brain tissue.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.